Literature DB >> 12865160

The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase.

Lincoln Edwards1, Paul Ernsberger.   

Abstract

We sought to further elucidate signal transduction pathways for the I(1)-imidazoline receptor in PC12 cells and their interaction with the well-characterized signaling events triggered by nerve growth factor (NGF) in these cells. Stimulation of the I(1)-imidazoline receptor with moxonidine, a centrally acting antihypertensive, increased by greater than two-fold the proportion of ERK-1 and ERK-2 in the phosphorylated active form. Similarly, NGF elicited a five-fold increase in activated ERKs. Surprisingly, treatment of NGF-treated cells with moxonidine completely reversed activation of ERK. Moxonidine-induced inhibition of ERK activation in NGF-treated cells was dose-dependent, followed a limited time course and could be blocked by the I(1)-antagonist efaroxan. These data suggested possible deactivation of ERK by specific phosphatases. Therefore, we assayed levels of MKP-2, a dual specificity phosphatase whose substrates include ERK. Moxonidine and NGF both increased levels of MKP-2 by three-fold. These effects were additive, as both agents together increased MKP-2 by a total of six-fold. Moxonidine-induced induction of MKP-2 was time- and dose-dependent and could be blocked by the I(1)-antagonist efaroxan or by D609, an inhibitor of phosphatidylcholine-selective phospholipase C known to block downstream signaling events coupled to I(1)-receptors. Thus, I(1)-receptors can abrogate the primary signaling cascade activated by NGF, most likely by increasing levels of a specific phosphatase to return dually phosphorylated ERK to its unphosphorylated state.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865160     DOI: 10.1016/s0006-8993(03)02893-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

1.  I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline.

Authors:  Yaron D Barac; Orit Bar-Am; Esti Liani; Tamar Amit; Luba Frolov; Elena Ovcharenko; Itzchak Angel; Moussa B H Youdim; Ofer Binah
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

2.  The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity.

Authors:  Laura Micheli; Lorenzo Di Cesare Mannelli; Fabio Del Bello; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Donatello Carrino; Alessandra Pacini; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

Review 3.  Brain stem adenosine receptors modulate centrally mediated hypotensive responses in conscious rats: A review.

Authors:  Noha N Nassar; Abdel A Abdel-Rahman
Journal:  J Adv Res       Date:  2014-12-18       Impact factor: 10.479

4.  Regulation of angiopoietin-1/Tie-2 receptor signaling in endothelial cells by dual-specificity phosphatases 1, 4, and 5.

Authors:  Raquel Echavarria; Sabah N A Hussain
Journal:  J Am Heart Assoc       Date:  2013-12-05       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.